Celltrion Pharm Unveils Dual Payload ADC Platform for the First Time at World’s Largest Cancer Conference

Presentation of ADC Dual Payload Research Results at AACR 2025 in the United States

Participating in the American Association for Cancer Research (AACR 2025) held in Chicago, USA, presenting a poster on ADC research results. Photo by Celltrion Pharm

Celltrion Pharm announced on May 2 that it participated in the American Association for Cancer Research (AACR 2025), held in Chicago, USA, from April 25 to 30 (local time), and for the first time presented research results on its ADC (antibody-drug conjugate) platform technology. AACR is considered the world's largest international conference in the field of oncology.

The "CTPH-02," unveiled for the first time in a poster format, is a dual payload type that combines a novel payload with a different mechanism of action with an existing payload (payload: cytotoxic anticancer drug). Celltrion Pharm independently developed and applied this new payload, which can generate synergy with the existing payload.

In general, dual payloads are known to exhibit stronger cytotoxicity against cancer cells compared to single payloads. When combined with an antibody, the effect at the target site is maximized.

Celltrion Pharm combined MMAE (monomethyl auristatin E, a microtubule inhibitor) and a novel payload with trastuzumab, a HER2 antibody. As a result, strong cytotoxicity was demonstrated through high synergy not only in cell lines with high HER2 expression but also in those with low expression levels. Notably, even when using MMAE with a low drug-antibody ratio (DAR), the dual payload ADC showed efficacy equal to or greater than that of a single payload ADC using MMAE with a high DAR.

Celltrion Pharm plans to continue developing CTPH-02 with the goals of increasing the maximum tolerated dose (MTD), decreasing the minimum effective dose (MED), expanding the patient population by securing cytotoxicity in cell lines with low antigen expression, and reducing drug resistance.

A Celltrion Pharm representative stated, "This AACR presentation marks a new paradigm in ADC design strategy by introducing our independently developed payload technology to create a combination of two different payloads," and added, "Celltrion Pharm will do its utmost to provide broader treatment options in the ADC field through continued development."

This content was produced with the assistance of AI translation services.